Popular

Once or perhaps twice a year, something happens to a stock that smacks it down on strong volume. These events are usually triggered by misunderstandings or disinformation

As we near the end of the dog days of August, the relatively sleepy and under-followed Plandaí¬ Biotechnology, Inc. (OTCQB – PLPL - $0.61 - Spec Buy) has matched its 52-week high this week and appears primed to move substantially higher.

Given the substantial costs to administer and conduct clinical trials exclusively in the U.S., it is likely that Nuvilex, Inc. (OTCQB – NVLX- $0.165 – Spec Buy) will elect to turn to overseas locations for future clinical trials.

With a flurry of news on the research and development front in recent weeks, it appears as if investors have forgotten about the market opportunity in Europe that lies ahead for Plandaí¬ Biotechnology (OTC QB – PLPL - $0.54 – Spec Buy).

In addition to its success wildly successful digital publishing business, LifeApps Digital Media, Inc. (OTCQB – LFAP - $0.07 – Spec Buy) is having a solid 2H13 selling promotional and personalized team athletic apparel products via its subsidiary the Sports One Group.

When one lifts up the hood, one realizes that a sleeping giant in the form of highly successful animal trials to treat mammary tumors may emerge as a real blockbuster for Nuvilex.

With the return of its CEO from a highly successful trip in Ghana, INSCOR, Inc. (OTCQB – IOGA – Spec Buy), along with the other partners associated with an impressive mass social welfare initiative, is gearing up for the 4Q13 launch of the program, which could eventually encompass as many as 650 million living in poverty in Africa.